Skip to content

Dermatological safety Study of Cosmetics on healthy human volunteers

Human Repeat Insult Patch Test (HRIPT) to Evaluate the Dermal Irritation and Sensitization Potential of a Hypochlorous Acid Spray on Healthy Human Volunteers with or without Sensitive Skin. - Nil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103129
Enrollment
100
Registered
2026-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Arm- Hypochlorous Acid: 40 l of investigational product (without dilution) on the pre-cut filter paper placed inside the allotted derma proof Aluminium Finn chamber prefixed to a m

Sponsors

Josh and Quinn Pte. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Able and willing to provide written informed consent. 2.Available for entire 6 8-week study duration. 3. Fitzpatrick skin type determined (I VI) with intentional inclusion of darker skin types (V VI) per NEA guidance. 4. Healthy intact skin on test sites (upper back/volar forearm) without sunburn, wounds, or active dermatitis. 5. For sensitive/eczema-prone group: self-reported history of eczema or sensitive skin but stable condition. 6. Willing to refrain from new topical or systemic skin treatments during study. 7. Agree to avoid sun exposure, swimming, and vigorous exercise during patching periods.

Exclusion criteria

Exclusion criteria: 1.Active flare of eczema/atopic dermatitis, psoriasis, acne,or infection on the test site. 2. Known hypersensitivity to adhesives, occlusive patches,or any study product ingredients. 3. Systemic corticosteroid, immunosuppressive, or antihistamine therapy within 14 days. 4. Topical corticosteroid or retinoid use on test site within 7 days. 5. History of keloid scarring or poor wound healing. 6. Pregnancy or lactation. 7. Participation in another investigational study within 30 days. 8. Any condition judged by investigator to interfere with the test or safety evaluation.

Design outcomes

Primary

MeasureTime frame
1.To determine the irritation and/or sensitization potential of a test material 2.In support of sensitive skin claims and supporting evidence for hypoallergenicity claims after repeated application under occlusive or semi-occlusive patches to the skin of human subjects.Timepoint: Day 1 to Day 40

Secondary

MeasureTime frame
Incidence & rate of adverse events.Timepoint: Day 1 to Day 40

Countries

India

Contacts

Public ContactDr Ashok Godavarthi

Radiant Research Services Pvt Ltd

surya.ashok@gmail.com09880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026